Back to Hepatology
Hepatologyv2008Evidence-Based

BARD Score for NAFLD Fibrosis

Predicts risk of advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). The BARD score uses three simple clinical parameters (BMI, AST/ALT ratio, and diabetes) to identify patients at low risk of advanced fibrosis who may not require liver biopsy.

Clinical Input Parameters

kg/m²
Range: 10 — 70 kg/m²
U/L
Range: 1 — 5000 U/L
U/L
Range: 1 — 5000 U/L
Clinical Assessment
Awaiting Parameters
bard score
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The BARD Score for NAFLD Fibrosis is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within hepatology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

BARD Score = BMI ≥28 (1 point) + AST/ALT ratio ≥0.8 (2 points) + Diabetes (1 point)

Clinical Pearls & Practice Notes

  • BARD stands for BMI, AST/ALT Ratio, Diabetes
  • Score ranges from 0 to 4 points
  • Developed to identify NAFLD patients without advanced fibrosis
  • High negative predictive value (96%) for scores 0-1
  • Consider additional testing (FibroScan, MR elastography) for high-risk patients
  • Not validated for use in patients with other liver diseases

Evidence & Literature Citations

  1. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008 Oct;57(10):1441-7. doi: 10.1136/gut.2007.146019.
  2. Raszeja-Wyszomirska J, Szymanik B, Ławniczak M, Kajor M, Chwist A, Milkiewicz P, et al. Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD). BMC Gastroenterol. 2010 Jun 17;10:67. doi: 10.1186/1471-230X-10-67.
  3. Cichoż-Lach H, Celiński K, Prozorow-Król B, Swatek J, Słomka M, Lach T. The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease. Med Sci Monit. 2012 Dec;18(12):CR735-40. doi: 10.12659/msm.883601.

Score Interpretation Ranges

Low Risk0 – 1 pts

Low risk of advanced fibrosis

High Risk2 – 4 pts

High risk of advanced fibrosis

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.